Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165992 | 0.92 | IKBKB (0.44) | IKBKBMALT1 | |
| SCHEMBL1685202 | 0.87 | MAPKAPK5 (0.41) | PIK3CAMTORIKBKBMEN1KMT2A | |
| SCHEMBL1685199 | 0.87 | MAPKAPK5 (0.41) | PIK3CAMTORIKBKBMEN1KMT2A | |
| SCHEMBL14162589 | 0.83 | MAPKAPK5 (0.39) | PIK3CAMTORMALT1DRD2MAPKAPK5 | |
| SCHEMBL13922260 | 0.80 | MAPKAPK5 (0.41) | IKBKBMALT1DRD2MAPKAPK5 | |
| SCHEMBL10166023 | 0.80 | CSF1R (0.39) | PIK3CAMTORMAPKAPK5 | |
| SCHEMBL10166432 | 0.79 | MAPKAPK5 (0.35) | MAPKAPK5 | |
| SCHEMBL10166168 | 0.79 | PTK6 (0.38) | PIK3CAMTORMAPKAPK5 | |
| SCHEMBL1685179 | 0.78 | MAPKAPK5 (0.44) | IKBKBMALT1DRD2MAPKAPK5 | |
| SCHEMBL1685180 | 0.78 | MAPKAPK5 (0.44) | IKBKBMALT1DRD2MAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | PIK3CA 1298/4885MTOR 1365/4885IKBKB 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.